Cassava Sciences, Inc. (SAVA)

19.64 -1.55 (-7.31%) 收市：04:00PM EDT

Cassava Sciences, Inc.

6801 N. Capital of Texas Highway
Suite 300 Building 1
Austin, TX 78731
United States
512 501 2444
https://www.cassavasciences.com

版塊: Healthcare
行業: Biotechnology
全職員工: 29

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Remi Barbier	Founder, Chairman, President & CEO	1.2M	598.57k	1960
Mr. Eric J. Schoen	Chief Financial Officer	460k	無	1968
Mr. R. Christopher Cook	Senior VP, Company Secretary & General Counsel	425k	無	1964
Dr. James W. Kupiec M.D.	Chief Medical Officer	435k	無	1953
Dr. George Thornton Ph.D.	Senior Vice President of Technology	無	無	無
Mr. Michael Zamloot	Senior Vice President of Technical Operations	無	無	無
Dr. Michael Marsman Pharm.D.	Senior Vice President of Regulatory Affairs	無	無	無
Dr. Lindsay H. Burns Ph.D.	Senior Vice President of Neuroscience	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

公司管治

截至 2024年4月1日 止，Cassava Sciences, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：10；董事會：10；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。